



Antibody Drug Discovery for Cancer

Guest Editor:

Dr. Junquan Liu

The University of Texas Health
Science Center at Houston, 1825
Pressler St, 501R, Houston, TX
77030, USA

Deadline for manuscript
submissions:

31 May 2024

Message from the Guest Editor

Dear Colleagues,

Characterized by an excellent specificity, high-level affinity, long serum half-life, and immune effector function, antibodies have been a powerful weapon against cancer since the approval of the first antibody drug (rituximab) in 1997. Some alternative formats for approved antibody drugs include antibody-drug conjugates and bispecific antibodies. The successful application of antibody drugs in oncology has encouraged the development of next-generation antibodies with an enhanced response.

This Special Issue aims to publish original research and review articles focused on (but not limited to) the development of new monoclonal antibodies, nanobodies, ADCs, and bispecific antibodies for cancer treatment. Meanwhile, papers related to the translation of antibody drugs and evaluations in clinical trials are welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)